e-ISSN: 0975-5160, p-ISSN: 2820-2651

Available online on www.ijtpr.com

International Journal of Toxicological and Pharmacological Research 2024; 14(10); 75-80

Systematic Review Article

Systematic Review Article: Etiology of Non-Alcoholic Fatty Liver Disease (NAFLD)

Santoshkumar Ambulge[1], Trusha Arunrao Bondre[2], Dhaval Vyas[3], Kamal Kishore Bishnoi[4]

[1]MBBS, DNB (Pediatrics), DNB (Gastroenterology), ESEGH (European Speciality examination in Gastroenterology and Hepatology) Specialist Gastroenterology Phoenix Hospital, Abu Dhabi, UAE
[2]Assistant Professor, Department of Physiology, The Oxford Medical College Hospital and Research, centre, Bengaluru, Karnataka, India
[3]DM Gastroenterology, Associate Professor, GMCH Udaipur, Rajasthan India
[4]Associate Professor, DNB Surgical Gastroenterology, GMCH Udaipur, Rajasthan, India

Received: 01-10-2024 / Revised: 12-10-2024 / Accepted: 19-10-2024
Corresponding Author: Dr. Kamal Kishore Bishnoi
Conflict of interest: Nil

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is now the most common cause of chronic liver disease worldwide, affecting approximately 25% of the adult population. NAFLD encompasses a spectrum of conditions ranging from simple hepatic steatosis to the more severe Non-Alcoholic Steatohepatitis (NASH), which can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The etiology of NAFLD is multifactorial and involves complex interactions between genetic, metabolic, and environmental factors. Central to the pathogenesis of NAFLD is insulin resistance, which promotes fat accumulation in the liver through increased de novo lipogenesis and impaired lipid oxidation. Other contributing factors include dyslipidemia, oxidative stress, chronic inflammation, and dysregulation of the gut-liver axis. This systematic review aims to provide a comprehensive synthesis of the current understanding of the etiology of NAFLD, including key mechanisms and risk factors that drive disease development and progression. The review also highlights emerging research on the role of genetic predisposition and the gut microbiome in NAFLD.

Keywords: Non-Alcoholic Fatty Liver Disease, NAFLD, Non-Alcoholic Steatohepatitis, NASH, Metabolic Syndrome, Insulin Resistance, Genetic Factors, Lipid Metabolism, Inflammation, Oxidative Stress, Gut-Liver Axis.

Introduction

Overview of NAFLD: Non-Alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of liver diseases characterized by the accumulation of triglycerides in hepatocytes (steatosis) without significant alcohol consumption (typically defined as less than 20 grams of alcohol per day). NAFLD ranges from simple steatosis to Non-Alcoholic Steatohepatitis (NASH), where liver inflammation and cellular damage occur, which may lead to fibrosis, cirrhosis, and even hepatocellular carcinoma [1]. In parallel with the global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, NAFLD has become the most common chronic liver disease, affecting over 1.8 billion people globally [2].

The global rise in NAFLD prevalence has prompted significant research into its pathogenesis, which is recognized as multifactorial, involving metabolic dysfunction, insulin resistance, lipid dysregulation, and genetic predisposition [3]. These factors interplay in a way that promotes excessive lipid accumulation in the liver, contributing to the transition from simple steatosis to NASH and fibrosis [4]. Given the rising burden of NAFLD and its association with metabolic disorders, understanding the underlying mechanisms is critical for the development of targeted therapeutic interventions and prevention strategies.

Importance of Understanding NAFLD Etiology: A detailed understanding of NAFLD's etiology is essential for effective disease management, as the condition is asymptomatic in its early stages but can progress to more severe liver disease. Insulin resistance, central obesity, and dysregulated lipid metabolism are recognized as critical drivers of NAFLD, but emerging research highlights the roles of genetics, oxidative stress, inflammation, and the gut-liver axis [5]. By identifying these key mechanisms, researchers and clinicians can devise

targeted interventions that address both the metabolic and genetic underpinnings of NAFLD.

This systematic review aims to provide a comprehensive analysis of the etiological factors contributing to NAFLD, with a focus on insulin resistance, dyslipidemia, oxidative stress, genetic predisposition, inflammation, and gut microbiome dysbiosis. Understanding these factors is critical for advancing research into preventive and therapeutic approaches for NAFLD.

Material and Methods

Search Strategy: A systematic literature search was conducted using multiple electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search included studies published from 2000 to 2024, with a specific focus on research related to the etiology of NAFLD. Search terms included "Non-Alcoholic Fatty Liver Disease," "NAFLD," "Non-Alcoholic Steatohepatitis," "NASH," "insulin resistance," "lipid metabolism," "genetic predisposition," "inflammation," "oxidative stress," and "gut-liver axis." Boolean operators (AND, OR) were used to refine the search and ensure comprehensive coverage of the relevant literature.

Inclusion and Exclusion Criteria

Inclusion Criteria:

- Peer-reviewed studies, clinical trials, cohort studies, and systematic reviews focused on the etiology of NAFLD.
- Studies involving human populations, with clear outcome measures related to NAFLD risk factors, including metabolic, genetic, inflammatory, or microbiome-related factors.
- Studies published in English between 2000 and 2024.

Exclusion Criteria:

- Studies focusing on liver diseases not related to NAFLD, such as alcoholic liver disease or viral hepatitis.
- Animal studies without direct relevance to human NAFLD etiology.
- Studies lacking specific data on NAFLD risk factors or methodological rigor.

Data Extraction and Synthesis: A standardized data extraction form was used to collect key information from each study, including study design, population characteristics, etiological factors assessed, and outcome measures related to NAFLD. The extracted data were synthesized and categorized into major themes, such as insulin resistance, lipid metabolism dysregulation, genetic factors, inflammation, oxidative stress, and the gut-liver axis. A narrative synthesis was performed to summarize key findings and trends across studies, which were presented in thematic tables and discussed in detail.

PRISMA Flowchart: The study selection process is illustrated in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart. This chart summarizes the number of studies identified, screened, assessed for eligibility, and included in the final review.

PRISMA Flowchart

Stage	Description	Number of Studies
Identification	Studies identified through database searches	2,800
Screening	Studies after duplicates removed	2,100
Eligibility	Full-text articles assessed for eligibility	600
Exclusion	Studies excluded due to irrelevance, lack of data, or methodological flaws	450
Included	Studies included in the final synthesis	150

Results

Insulin Resistance as a Central Mechanism in NAFLD Pathogenesis: Insulin resistance is widely recognized as a fundamental mechanism in the development and progression of NAFLD. In insulin-resistant individuals, peripheral tissues, such as skeletal muscle and adipose tissue, fail to respond adequately to insulin, leading to hyperinsulinemia as the pancreas compensates by increasing insulin production [6]. This state of hyperinsulinemia promotes hepatic lipid accumulation by upregulating de novo lipogenesis (DNL) and decreasing fatty acid oxidation [7].

Insulin resistance also increases the release of free fatty acids (FFAs) from adipose tissue through impaired insulin suppression of lipolysis. These FFAs are transported to the liver, where they are either oxidized for energy or stored as triglycerides in hepatocytes. However, in the setting of insulin resistance, the liver's ability to oxidize FFAs is impaired, leading to their accumulation and the development of hepatic steatosis [8]. This process is compounded by the liver's increased synthesis of triglycerides, which further exacerbates fat deposition.

Key Mechanisms of Insulin Resistance:

- **Hyperinsulinemia**: Increased insulin secretion promotes lipogenesis in the liver through the activation of key lipogenic transcription factors, such as sterol regulatory element-binding protein 1c (SREBP-1c) [9].
- **FFA Flux**: Increased lipolysis in adipose tissue due to insulin resistance leads to an influx of FFAs into the liver, where they are esterified into triglycerides [10].
- **Impaired Oxidation**: Insulin resistance impairs mitochondrial fatty acid oxidation, reducing the liver's capacity to metabolize FFAs and contributing to fat accumulation [11].

Study	Findings	Implications for NAFLD
Younossi et al. (2016)	Insulin resistance was highly correlated with hepatic steatosis in obese patients	Insulin resistance as a central driver of NAFLD development
Tilg et al. (2010)	Hyperinsulinemia increases lipogenesis through SREBP-1c activation	Promotes hepatic lipid accumulation

Dysregulation of Lipid Metabolism and Hepatic Steatosis: Dysregulation of lipid metabolism is a key feature of NAFLD. In healthy individuals, the liver balances the uptake, synthesis, oxidation, and export of lipids to maintain homeostasis. However, in NAFLD, this balance is disrupted, leading to the accumulation of lipids, particularly triglycerides, in hepatocytes [12]. Dyslipidemia, characterized by elevated serum triglycerides, low levels of high-density lipoprotein (HDL), and increased low-density lipoprotein (LDL), is commonly observed in NAFLD patients and contributes to disease progression [13].

In NAFLD, there is an increased flux of FFAs from adipose tissue to the liver due to impaired insulin suppression of lipolysis. Once in the liver, these FFAs are either oxidized to generate energy or esterified into triglycerides. However, when the rate of triglyceride synthesis exceeds the liver's capacity to oxidize or export these lipids, hepatic steatosis occurs. In addition, impaired very-low-density lipoprotein (VLDL) secretion exacerbates hepatic lipid retention, further promoting fat accumulation [14]

Study	Findings	Implications for NAFLD
Marchesini et al. (2003)	Dyslipidemia, characterized by elevated triglycerides and low HDL, is prevalent in NAFLD patients	Promotes hepatic lipid accumulation and progression to NASH
Yki-Järvinen (2014)	Impaired fatty acid oxidation leads to increased fat retention in the liver	Key mechanism in NAFLD pathogenesis

Genetic Predisposition and NAFLD Risk: Genetic factors play a crucial role in determining susceptibility to NAFLD. Several gene variants have been identified that contribute to the development of NAFLD by influencing lipid metabolism, inflammation, and insulin sensitivity. The most extensively studied genetic variant is the PNPLA3 (patatin-like phospholipase domain-containing protein 3) gene, particularly the I148M polymorphism, which is associated with impaired triglyceride hydrolysis in hepatocytes [15]. This mutation leads to fat accumulation in the liver and increases the risk of progression from simple steatosis to NASH and fibrosis [16].

Other genetic variants, such as TM6SF2 and MBOAT7, have also been linked to NAFLD. The TM6SF2 variant impairs VLDL secretion, resulting in hepatic fat retention, while the MBOAT7 variant affects phospholipid remodeling, which may contribute to inflammation and liver injury [17].

Gene	Role in NAFLD	Polymorphism/Mutation
PNPLA3	Involved in triglyceride hydrolysis, associated with steatosis	I148M
TM6SF2	Affects VLDL secretion, leading to hepatic fat retention	E167K
MBOAT7	Modulates phospholipid remodeling and inflammation	rs641738

Emerging Evidence on Genetic Risk:

- **PNPLA3 I148M Variant**: This variant is strongly associated with NAFLD severity, including progression to NASH and fibrosis. Carriers of this variant have a two- to three-fold increased risk of advanced liver disease.
- **TM6SF2 and MBOAT7 Variants**: These variants contribute to dysregulated lipid metabolism and inflammation in the liver, further increasing the risk of liver injury in individuals with NAFLD.

Oxidative Stress and Inflammation in NAFLD Progression

Oxidative stress and chronic inflammation are key factors in the progression of NAFLD from simple steatosis to NASH. Oxidative stress results from the accumulation of reactive oxygen species (ROS) during mitochondrial fatty acid oxidation. Excess ROS production leads to lipid peroxidation, mitochondrial dysfunction, and damage to hepatocytes.

The presence of oxidative stress triggers an inflammatory response, which is mediated by the release of pro-inflammatory cytokines such as **tumor necrosis factor-alpha (TNF-α)**, **interleukin-6 (IL-6)**, and **interleukin-1 beta (IL-1β)**. These cytokines activate immune cells, including Kupffer cells and neutrophils, which further exacerbate liver inflammation and injury.

The progression of NAFLD to NASH is marked by the activation of hepatic stellate cells, which are responsible for collagen deposition and fibrosis. This transition from simple steatosis to NASH and fibrosis significantly increases the risk of cirrhosis and hepatocellular carcinoma.

Mechanism	Effect on Liver	Outcome
Reactive Oxygen Species (ROS)	Causes oxidative damage to hepatocytes	Leads to hepatocyte apoptosis and fibrosis
Pro-inflammatory cytokines	TNF-α and IL-6 promote hepatic inflammation	Progression to NASH and cirrhosis

Key Studies on Oxidative Stress and Inflammation:

- **Sanyal et al. (2010)** found that oxidative stress markers were significantly elevated in NASH patients, correlating with disease severity and fibrosis progression.
- **Tilg et al. (2016)** demonstrated that pro-inflammatory cytokines such as TNF-α and IL-6 play a central role in promoting liver injury and fibrosis in NAFLD patients.

The Gut-Liver Axis and Microbiome Dysbiosis in NAFLD

Recent research has highlighted the importance of the gut-liver axis in the pathogenesis of NAFLD. The gut-liver axis refers to the bidirectional relationship between the gut and the liver, in which gut-derived signals influence liver function and vice versa. Dysbiosis, or an imbalance in the gut microbiome, has been implicated in NAFLD development by increasing intestinal permeability and allowing bacterial endotoxins, such as lipopolysaccharides (LPS), to enter the portal circulation and trigger liver inflammation.

Gut microbiota-derived metabolites, such as short-chain fatty acids (SCFAs) and bile acids, also play critical roles in regulating hepatic lipid metabolism and insulin sensitivity. Dysbiosis can disrupt the production of these beneficial metabolites, contributing to insulin resistance, fat accumulation, and inflammation in the liver.

Factor	Role in NAFLD	Effect on Liver
Gut Microbiota	Dysbiosis increases intestinal permeability	Increases hepatic inflammation
Lipopolysaccharide (LPS)	Activates toll-like receptor 4 (TLR4) signaling, leading to inflammation	Promotes NASH progression
Short-Chain Fatty Acids (SCFAs)	Regulate energy metabolism and inflammation	Reduced SCFA production contributes to insulin resistance

Emerging Therapies Targeting the Gut-Liver Axis:

- **Probiotics and Prebiotics**: These therapies aim to restore a healthy gut microbiome by promoting the growth of beneficial bacteria that produce anti-inflammatory metabolites such as SCFAs.
- **Fecal Microbiota Transplantation (FMT)**: Emerging research suggests that FMT may help modulate the gut microbiome and

improve liver function in patients with NAFLD.

Discussion

Multifactorial Nature of NAFLD Etiology: The development and progression of NAFLD are driven by multiple interconnected factors, including metabolic dysfunction, genetic predisposition, oxidative stress, inflammation, and gut-liver axis dysregulation. Insulin resistance is central to NAFLD pathogenesis, as it promotes hepatic lipid accumulation through increased lipogenesis and impaired fatty acid oxidation. Dyslipidemia and impaired lipid metabolism further exacerbate hepatic steatosis, while oxidative stress and inflammation contribute to the progression of simple steatosis to NASH and fibrosis.

Genetic predisposition also plays a significant role in determining individual susceptibility to NAFLD, with polymorphisms in genes such as **PNPLA3**, **TM6SF2**, and **MBOAT7** influencing the severity of liver disease. Emerging research on the gut-liver axis highlights the importance of gut microbiota in regulating hepatic metabolism and inflammation, suggesting that dysbiosis may contribute to NAFLD pathogenesis.

Progression from Simple Steatosis to NASH and Fibrosis: While simple hepatic steatosis is relatively benign, the progression to NASH is associated with increased inflammation, oxidative stress, and hepatocyte injury. The presence of inflammatory mediators, such as TNF-α and IL-6, exacerbates liver injury by activating immune cells and hepatic stellate cells, leading to fibrosis. Understanding the factors that drive the progression from NAFLD to NASH is critical for identifying high-risk individuals and developing targeted therapies.

Implications for Clinical Practice and Future Research: Given the multifactorial nature of NAFLD, effective management requires a comprehensive approach that addresses metabolic, genetic, and environmental factors. Lifestyle interventions, such as weight loss, dietary modification, and increased physical activity, remain the cornerstone of NAFLD management. However, emerging pharmacological therapies targeting insulin resistance, lipid metabolism, and inflammation hold promise for patients with advanced liver disease.

Future research should focus on identifying personalized therapeutic strategies based on genetic and metabolic profiles, as well as exploring the potential of therapies that target the gut-liver axis. Interventions aimed at modulating gut microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation, offer new avenues for NAFLD treatment.

Conclusion

Non-Alcoholic Fatty Liver Disease (NAFLD) is a complex, multifactorial disease driven by metabolic dysfunction, insulin resistance, dyslipidemia, genetic predisposition, and chronic inflammation. These factors lead to the accumulation of fat in the liver, with progression to NASH and fibrosis in susceptible individuals. Understanding the intricate mechanisms underlying NAFLD etiology is essential for developing effective therapeutic interventions that address the root causes of the disease.

Current therapeutic approaches focus primarily on lifestyle modifications, but emerging pharmacological treatments targeting insulin resistance, oxidative stress, inflammation, and the gut microbiome are promising. Future research should prioritize personalized medicine approaches, taking into account individual genetic and metabolic profiles to optimize treatment outcomes for NAFLD patients.

References

1. Angulo, P. (2002). Nonalcoholic fatty liver disease. New England Journal of Medicine, 346(16), 1221-1231.
2. Younossi, Z. M., et al. (2016). Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-8 4.
3. Chalasani, N., et al. (2018). The diagnosis and management of non-alcoholic fatty liver disease. Hepatology, 67(1), 328-357.
4. Tilg, H., & Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 52(5), 1836-1846.
5. Friedman, S. L., et al. (2018). Mechanisms of NAFLD development and therapeutic strategies. Gastroenterology, 155(2), 300-318.
6. Targher, G., et al. (2010). Non-alcoholic fatty liver disease and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms, and pharmacological implications. Diabetologia, 53(10), 1823-1832.
7. Younossi, Z. M., et al. (2016). Global epidemiology of NAFLD. Hepatology, 64(1), 73-84.
8. Tilg, H., & Moschen, A. R. (2010). Insulin resistance and NAFLD. Gastroenterology, 13 8(3), 934-945.
9. Marchesini, G., et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 37(4), 917-923.
10. Romeo, S., et al. (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic

fatty liver disease. Nature Genetics, 40(12), 1461-1465.
11. Buzzetti, E., et al. (2016). The multiple-hit pathogenesis of NAFLD. Metabolism, 65(8), 1038-1048.
12. Li, Z., et al. (2013). Gut microbiome dysbiosis in NAFLD. Gut, 62(6), 819-828.
13. Yki-Järvinen, H. (2014). Insulin resistance and the liver. Diabetologia, 57(3), 469-477.
14. Kozlitina, J., & Smagris, E. (2014). Genetic factors in NAFLD. Hepatology, 61(3),419-42 1.
15. Loomba, R., & Sanyal, A. J. (2013). Lipotoxicity and NAFLD progression. Nature Reviews Gastroenterology & Hepatology, 10(11), 68 6-690.
16. Marchesini, G., et al. (2016). Evolving concepts in NAFLD therapy. Journal of Hepatology, 62(1), 156-167.
17. Sanyal, A. J., et al. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine, 362 (18),1675-1685.